Several authors suggested that the mutation of IDH1 could occur in early stages of the glioma formation and could lead to tumor progression towards GBM (Juratli et al., 2012; Lewandowska et al., 2014; Thota et al., 2012; Weller et al., 2011). Here, IDH1 is linked to central nervous system cancer.